PHOENIX, Ariz. -- A son's passion to find a cure for the cancer that claimed the life of his mother has led to a new series of clinical trials under a Translational Genomics Research Institute (TGen) initiative to find a cure for pancreatic cancer.
The 'Seena I' clinical trial is named for Seena Magowitz, a cancer research advocate and patient who fell victim to pancreatic cancer the nation's fourth leading cause of cancer death.
Pancreatic cancer patients can soon enroll in Seena I, which is planned for at least four clinical sites across the nation, including Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare.
The Pancreatic Cancer Research Team (PCRT) will supervise the Seena trials. PCRT is a worldwide consortium of 45 clinical institutions led by TGen and dedicated to finding a cure for pancreatic cancer.
For nearly a decade, Scottsdale resident Roger Magowitz has championed research into finding a cure for pancreatic cancer, a disease that took the life of his mother, Seena, in 2001.
"I am deeply honored and filled with tremendous hope that the clinical trials named for my mother, Seena, will lead perhaps within just a few years to an actual cure for pancreatic cancer," said Roger Magowitz, President of the Seena Magowitz Foundation, who has donated $1 million to the TGen pancreatic cancer initiative.
The pancreas is a gland behind the stomach that secretes enzymes into the upper part of the small intestine to help digestion. It also produces hormones, including insulin, which helps regulate the metabolism of sugars.
The Seena I trial consists of three treatment components:
|Contact: Steve Yozwiak|
The Translational Genomics Research Institute